Q Contains Benzene Ring Patents (Class 514/602)
Nitrogen in q (Class 514/603)
Q is monocyclic (Class 514/604)
  • Pharmaceutically active sulfanilide derivatives
    Publication number: 20040072816
    Abstract: The present invention relates to sulfanilide derivatives of formula (I), in which R1 and R2 are optionally substituted aryl and heteroaryl groups and the other variables are as defined in the claims, for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such sulfanilide derivatives. Said derivatives are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to sulfanilide derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and/or vasopressin receptor.
    Type: Application
    Filed: September 25, 2003
    Publication date: April 15, 2004
    Inventors: Anna Quattropani, Matthias Schwarz, Catherine Joran-Lebrun, Dennis Church, Alexander Scheer
  • Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20040072802
    Abstract: The present application describes novel &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: October 9, 2002
    Publication date: April 15, 2004
    Inventors: Jingwu Duan, Bryan W. King, Carl Decicco, Thomas P. Maduskuie, Mathew E. Voss
  • NK1 antagonists
    Publication number: 20040072854
    Abstract: A NK1 antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough: 1
    Type: Application
    Filed: March 12, 2003
    Publication date: April 15, 2004
    Applicant: Schering Corporation
    Inventors: Michelle Laci Wrobleski, Gregory A. Reichard, Neng-Yang Shih, Dong Xiao
  • Cyclopentyl sulfonamide derivatives
    Publication number: 20040067984
    Abstract: The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: March 11, 2003
    Publication date: April 8, 2004
    Inventors: Buddy Eugene Cantrell, Winton Dennis Jones, Timothy Alan Shepherd, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Derivatives of C2-substituted indan-1-ol compounds, methods for their preparation and use
    Patent number: 6717008
    Abstract: Derivatives of C2-substituted indan-1-ol compounds, processes for their preparation and their use are disclosed. In particular, the invention relates to compounds of the formula I and to their physiologically acceptable salts and physiologically functional derivatives. The compounds are suitable, for example, for use as anorectics.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: April 6, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Methods for anti-tumor therapy
    Patent number: 6716879
    Abstract: Disclosed and claimed is a method for treating tumors using sulfonylamino-substituted N-aryl- or heteroarylcarboxamide derivatives.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: April 6, 2004
    Assignee: Compass Pharmaceuticals, LLC
    Inventor: Irwin Braude
  • Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors
    Patent number: 6716833
    Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: April 6, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy I. Levin, James M. Chen, Derek C. Cole, Mila T. Du, Leif M. Laakso
  • Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use
    Publication number: 20040063725
    Abstract: The present invention relates to novel N-(phenylsulphonyl)glycyl-glycine compounds, which are defined by formula I and the description, as well as their method of preparation and their use in therapeutics 1
    Type: Application
    Filed: June 20, 2003
    Publication date: April 1, 2004
    Inventors: Martine Barth, Michel Bondoux, Christophe Matt, Pierre Dodey, Jean-Michel Luccarini, Jean-Luc Paquet, Didier Pruneau
  • Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
    Publication number: 20040058926
    Abstract: The present invention provides methods for the treatment and prevention of ocular COX-2 mediated disorders using COX-2 inhibitors.
    Type: Application
    Filed: September 22, 2003
    Publication date: March 25, 2004
    Inventors: Rebanta Bandyopadhyay, David Eveleth, Tom Van Haarlem, Tugrul T Kararli, Satish K. Singh
  • Naphthalene derivatives
    Publication number: 20040053890
    Abstract: The present invention relates to novel naphthalene derivatives of formula (I), wherein R1, R2, R3 and X are as defined in the description, and preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.
    Type: Application
    Filed: May 19, 2003
    Publication date: March 18, 2004
    Inventors: Christopher Thomas Brain, Andrew James Culshaw, Edward Karol Dziadulewicz, Ulrich Schopfer
  • Endosulfan formulation and methods of use thereof
    Publication number: 20040054010
    Abstract: The present inventors have found that the contrasting chemical, physical and environmental characteristics of alpha and beta endosulfan provide an opportunity to formulate an effective endosulfan formulation with lower risk to the environment. Accordingly, the present invention provides a method for controlling or reducing pest numbers in an area affected or likely to be affected by pests, the method comprising applying to the area an endosulfan formulation, the formulation comprising beta endosulfan and alpha endosulfan, wherein the ratio of beta to alpha endosulfan in the formulation is at least 3.5:6.5 w/w.
    Type: Application
    Filed: September 22, 2003
    Publication date: March 18, 2004
    Inventors: Tara D. Sutherland, Michael J. Lacey, Robyn J. Russell, John G. Oakeshott
  • Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
    Publication number: 20040048907
    Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke.
    Type: Application
    Filed: May 15, 2003
    Publication date: March 11, 2004
    Inventors: Brian M. Aquila, Seth C. Hopkins, Curtis A. Lockshin, Fengjiang Wang
  • Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
    Publication number: 20040048891
    Abstract: The present invention provides a cytokine production inhibitor containing as an active ingredient an aniline derivative of the formula (I) or a salt thereof: 1
    Type: Application
    Filed: June 19, 2003
    Publication date: March 11, 2004
    Inventors: Fuminori Kato, Hirohiko Kimura, Shunji Yuki, Kazuhiro Yamamoto, Takashi Okada
  • Compounds for inhibiting insulin secretion and methods related thereto
    Publication number: 20040044049
    Abstract: Compounds, compositions and methods for altering insulin secretion, particularly in the context of treatment of subjects having, or suspected of being at risk for having, diabetes mellitus.
    Type: Application
    Filed: February 10, 2003
    Publication date: March 4, 2004
    Applicant: MitoKor
    Inventors: Yazhong Pei, Soumitra S. Ghosh, Ian William James
  • Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
    Patent number: 6699884
    Abstract: Methods of treating cyclooxygenase-2 mediated disorders comprising administering to a subject a therapeutically effective amount of one or more fluoro-substituted benzenesulfonyl compounds corresponding to Formula I: wherein A, X, n, R1, R2, and R3 are as described in the specification, and novel fluoro-substituted benzenesulfonyl compounds within Formula I.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: March 2, 2004
    Assignee: Pharmacia Corporation
    Inventors: David L. Brown, Matthew J. Graneto, Cindy L. Ludwig, John M. Molyneaux, John J. Talley
  • Modulation of CCR4 function
    Publication number: 20040039035
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Application
    Filed: September 2, 2003
    Publication date: February 26, 2004
    Applicants: Tularik Inc., ChemoCentryx, Inc.
    Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
  • Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
    Patent number: 6696480
    Abstract: A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include hypoxia-induced conditions. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: February 24, 2004
    Assignee: Brigham and Women's Hospital, Inc.
    Inventor: James K. Liao
  • Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors
    Patent number: 6693136
    Abstract: Compounds of formula (I) are novel P2X3 and P2X2/P2X3 containing receptor antagonists and are useful in treating pain, urinary incontinence, and bladder overactivity.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: February 17, 2004
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Meiqun Jiang, Richard A. Perner, Arthur Gomtsyan, Erol K. Bayburt, Guo Zhu Zheng
  • Sulphonamido-substituted bridged bicycloalkyl derivatives
    Publication number: 20040029862
    Abstract: A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.
    Type: Application
    Filed: February 5, 2003
    Publication date: February 12, 2004
    Inventors: Patrice Charles Belanger, Ian James Collins, Joanne Claire Hannam, Timothy Harrison, Stephen John Lewis, Andrew Madin, Edward Giles McIver, Alan John Nadin, Joseph George Neduvelil, Mark Steven Shearman, Adrian Leonard Smith, Timothy Jason Sparey, Graeme Irvine Stevenson, Martin Richard Teall
  • Polysubstituted indan-1-ol systems for the prophylaxis or treatment of obesity
    Patent number: 6686397
    Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed: Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: February 3, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Phosphate transport inhibitors
    Publication number: 20040019113
    Abstract: Disclosed are compounds which have been identified as inhibitors of phosphate transport.
    Type: Application
    Filed: December 20, 2002
    Publication date: January 29, 2004
    Applicant: GelTex Pharmaceuticals, Inc.
    Inventors: Thomas H. Jozefiak, Cecilia M. Bastos, Andrew T. Papoulis, Stephen Randall Holmes-Farley
  • Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
    Patent number: 6683210
    Abstract: Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: January 27, 2004
    Assignee: G. D. Searle & Co.
    Inventors: Daniel P Getman, Gary A DeCrescenzo, John N Freskos, Michael L Vazquez, James A Sikorski, Balekudru Devadas, Srinivasan Raj Nagarajan, David L Brown, Joseph J McDonald
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Publication number: 20040010020
    Abstract: A compound of Formula (IA) or Formula (IB) 1
    Type: Application
    Filed: May 28, 2003
    Publication date: January 15, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Thomas Martin Kirrane, Daniel Kuzmich, John Robert Proudfoot, David Thomson
  • Substituted phenylsulfonamide inhibitors of beta amyloid production
    Publication number: 20040006050
    Abstract: Compounds of Formula I, 1
    Type: Application
    Filed: June 9, 2003
    Publication date: January 8, 2004
    Applicants: Wyeth, ArQule Inc.
    Inventors: Anthony Frank Kreft, Derek Cecil Cole, Kevin Roger Woller, Joseph Raymond Stock, Kristina Martha Kutterer, Dennis Martin Kubrak, Charles William Mann, William Jay Moore, David Scott Casebier
  • Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient
    Publication number: 20040002493
    Abstract: A pharmaceutical composition, which comprises a benzoic acid derivative of formula (I) 1
    Type: Application
    Filed: February 27, 2003
    Publication date: January 1, 2004
    Inventors: Kousuke Tani, Masaki Asada, Kaoru Kobayashi, Masami Narita, Mikio Ogawa
  • Prodrugs of COX-2 inhibitors
    Publication number: 20040002522
    Abstract: A compound of Formula (I), or a pharmaceutically-acceptable salt thereof, suitable for use in the treatment of a cyclooxygenase-2 mediated disease is provided.
    Type: Application
    Filed: May 15, 2003
    Publication date: January 1, 2004
    Inventor: Jeffery S. Carter
  • Polysubstituted indan-1-ol compounds, and methods for their preparation and use
    Patent number: 6670401
    Abstract: Polysubstituted indan-1-ol compounds, methods for their preparation; and methods for their use are disclosed herein. In particular, the invention relates to polysubstituted indan-1-ol compounds of the formula I and their physiologically acceptable salts. The compounds are useful, for example, as anorectics.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: December 30, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Derivatives of C2-substituted indan-1-ol systems for the prophylaxis or treatment of obesity
    Patent number: 6667345
    Abstract: Derivatives of C2-substituted indan-1-ol compounds of the formula I: its physiologically acceptable salts, and its physiologically functional derivatives for the prophylaxis or treatment of obesity are disclosed herein. Compositions comprising the same, methods for preparing the instant compounds, and methods for reducing weight in mammals and for the prophylaxis or treatment of obesity are also described.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: December 23, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Non-covalent inhibitors of AmpC beta-lactamase
    Publication number: 20030232830
    Abstract: &bgr;-lactamases are the most widespread resistance mechanism to &bgr;-lactam antibiotics, such as penicillins and cephalosporins. In response to these enzymes, inhibitors have been introduced. Unfortunately, these inhibitors are also &bgr;-lactams, and resistance to them has developed rapidly. Consequently, the present invention provides a novel structure-based approach to inhibitors of these enzymes.
    Type: Application
    Filed: February 19, 2003
    Publication date: December 18, 2003
    Inventors: Brian K. Shoichet, Rachel A. Powers
  • Arylsulfonamidobenzylic compounds
    Publication number: 20030229093
    Abstract: Arylsulfonamidobenzyl alcohols, amines and sulfonamides are provided which are useful in treating lipid disorders, metabolic diseases and cell-proliferative diseases.
    Type: Application
    Filed: January 29, 2003
    Publication date: December 11, 2003
    Applicant: Tularik Inc.
    Inventors: Xian Yun Jiao, Frank Kayser, Sharon McKendry, Derek E. Piper, Andrew K. Shiau
  • Methods and reagents for the treatment of multiple sclerosis
    Publication number: 20030223959
    Abstract: The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological function in these patients.
    Type: Application
    Filed: April 17, 2003
    Publication date: December 4, 2003
    Inventors: Charles W. Stratton, William M. Mitchell, Subramaniam Sriram
  • Sulfonylguanidine compounds and pharmaceutical uses thereof
    Publication number: 20030225084
    Abstract: Sulfonylguanidine compounds corresponding to the tautomeric formulas I and Ia, a method for producing them, pharmaceutical compositions containing them, and methods of using them to prepare medicaments and for treating various medical conditions. The sulfonylguanidine compounds have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others.
    Type: Application
    Filed: March 31, 2003
    Publication date: December 4, 2003
    Applicant: Gruenenthal GmbH
    Inventors: Matthias Gerlach, Heinz Uragg, Michael Haurand, Claudia Katharina Puetz, Corinna Maul, Boris Chizh
  • Cancer remedy comprising anthranilic acid derivatives as active ingredients
    Publication number: 20030220402
    Abstract: A cancer remedy comprising a compound represented by the following formula as an active ingredient: 1
    Type: Application
    Filed: August 8, 2002
    Publication date: November 27, 2003
    Inventors: Naoki Tsuchiya, Takumi Takeyasu, Takashi Kawamura, Takao Yamori, Takashi Tsuruo
  • Heterocyclic arylsulfonamidobenzylic compounds
    Publication number: 20030220339
    Abstract: Heterocyclic arylsulfonamidobenzylic compounds are provided which are useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases.
    Type: Application
    Filed: January 29, 2003
    Publication date: November 27, 2003
    Applicant: Tularik Inc.
    Inventors: Xian Yun Jiao, Frank Kayser, David J. Kopecky, Sharon McKendry, Derek E. Piper, Andrew K. Shiau
  • N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them
    Publication number: 20030216392
    Abstract: The compounds of formula 1, 1
    Type: Application
    Filed: June 13, 2003
    Publication date: November 20, 2003
    Applicant: Dompe S.p.A.
    Inventors: Riccardo Bertini, Cinzia Bizzarri, Vilma Sabbatini, Gianfranco Caselli, Marcello Allegretti, Maria Candida Cesta, Carmelo Gandolfi, Marco Mantovanini, Francesco Colotta, Stefano Porzio
  • Pharmaceutical composition
    Publication number: 20030216475
    Abstract: The present invention relates to a pharmaceutical composition containing a compound represented by the formula: 1
    Type: Application
    Filed: January 29, 2003
    Publication date: November 20, 2003
    Inventors: Naoki Asakawa, Masao Nagao, Jun Sato
  • Phosphate transport inhibitors
    Publication number: 20030216449
    Abstract: N-Aryl-2-sulfonamidobenzamides, useful for treatment of chronic renal failure and uremic bone disease, are disclosed.
    Type: Application
    Filed: November 8, 2002
    Publication date: November 20, 2003
    Inventors: Joseph Weinstock, Gerald Girard, Dimitri Gaitanopoulos
  • Polyamine analogues as therapeutic and diagnostic agents
    Patent number: 6646149
    Abstract: Novel “bispolyamine” inhibitor compounds of polyamine transport are disclosed. These compounds are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. These compounds display desirable activities both for diagnostic and research assays and therapy.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: November 11, 2003
    Inventors: Nicolaas M. J. Vermeulin, Christine L. O'Day, Heather K. Webb, Mark R. Burns, Donald E. Bergstrom
  • Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
    Publication number: 20030207871
    Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.
    Type: Application
    Filed: February 19, 2003
    Publication date: November 6, 2003
    Inventors: Roger Dennis Tung, Michael Robin Hale, Christopher Todd Baker, Eric Steven Furfine, Istvan Kaldor, Wieslaw Mieczylaw Kazmierski, Andrew Spaltenstein
  • Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus
    Publication number: 20030203941
    Abstract: This invention provides compounds of formula I, having the structure 1
    Type: Application
    Filed: April 8, 2003
    Publication date: October 30, 2003
    Applicant: Wyeth
    Inventors: Joseph P. Sabatucci, Craig E. Caufield, Alexander A. Greenfield, Koi M. Morris, Eamonn P. Morrison
  • Combination of ablation and controlled drug delivery for the treatment of cancer
    Publication number: 20030199449
    Abstract: Provided is a new therapeutic method to treat cancer that combines radiofrequency (RF) ablation and local controlled drug delivery. A preferred method utilizes localized drug delivery of 5-fluorouricil (5-FU) from polyanhydride implants.
    Type: Application
    Filed: March 18, 2003
    Publication date: October 23, 2003
    Inventors: Peter J. Tarcha, John R. Haaga, Nick T. Stowe
  • Boronic ester and acid compounds, synthesis and uses
    Publication number: 20030199561
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Application
    Filed: March 19, 2003
    Publication date: October 23, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Compounds exhibiting thrombopoietin receptor agonism
    Publication number: 20030195231
    Abstract: Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism:
    Type: Application
    Filed: July 2, 2002
    Publication date: October 16, 2003
    Inventors: Hiroshi Takemoto, Takeshi Shiota, Masami Takayama
  • Use of bissulfonamides for producing medicines for the treatment of hyperlipidemia
    Patent number: 6632838
    Abstract: The use of bissulfonamides for producing medicines for the treatment of hyperlipidemia. The invention relates to the use of bissulfonamides and their salts for producing medicines for the treatment of hyperlipidemia. The use of compounds of formula I in which the radicals have the stated meanings, and of their salts for producing a medicine for the treatment of hyperlipidemia is described.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: October 14, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Reinhard Kirsch, Hans-Ludwig Schaefer, Eugen Falk, Norbert Krass
  • Novel bicyclic compounds
    Publication number: 20030191174
    Abstract: Compounds of the general formula (I): 1
    Type: Application
    Filed: October 28, 2002
    Publication date: October 9, 2003
    Inventors: Shunichi Ikuta, Shiro Miyoshi, Kohei Ogawa
  • Arylsulfonanilide derivates
    Patent number: 6630513
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: October 7, 2003
    Assignee: Tularix Inc.
    Inventors: Steven M. Rubenstein, Juan C. Jaen
  • Glyburidge composition
    Publication number: 20030185880
    Abstract: The present invention relates to a physical form of the known drug substance glyburide, also known as glibenclarnide, and chemically defined as 5-chloro-N-[2-[4-[[[(cyclohexylamino)-carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide (Merck Index, Tenth Edition, p. 642), as well as to dosage forms, e.g., tablets and capsules, incorporating said physical form of glyburide.
    Type: Application
    Filed: April 30, 2003
    Publication date: October 2, 2003
    Inventors: Gillian Cave, Sarah J. Nicholson
  • Substituted hydrazones as inhibitors of cyclooxygenase-2
    Publication number: 20030187035
    Abstract: Compounds useful as inhibitors of cyclooxygenase-2 activity have the formulae I or Ia: 1
    Type: Application
    Filed: December 10, 2002
    Publication date: October 2, 2003
    Inventors: E. Premkumar Reddy, M.V. Ramana Reddy
  • Use of 5HT-6 antagonists
    Patent number: 6627661
    Abstract: Methods for treating ADHD, comprising administering 5-HT6 antagonists to subjects having ADHD, are disclosed.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: September 30, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Charles Alan Reavill, Carol Routledge
  • Method of inhibiting matrix metalloproteinases
    Patent number: 6620835
    Abstract: The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: September 16, 2003
    Assignee: Warner-Lambert Company
    Inventors: Patrick Michael O'Brien, Joseph Armand Picard, Drago Robert Sliskovic, Andrew David White